Drug Profile
TX 153
Latest Information Update: 10 Aug 2017
Price :
$50
*
At a glance
- Originator OXIS International
- Class Anti-inflammatories
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders; Skin disorders
Most Recent Events
- 07 Aug 2017 Oxis International is now called GT Biopharma
- 21 Jun 2001 No-Development-Reported for Eye disorders in USA (Unknown route)
- 21 Jun 2001 No-Development-Reported for Skin disorders in USA (Unknown route)